Literature DB >> 23979954

Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program.

R Goldberg1, M Temprosa, J Otvos, J Brunzell, S Marcovina, K Mather, R Arakaki, K Watson, E Horton, E Barrett-Connor.   

Abstract

CONTEXT: Although intensive lifestyle change (ILS) and metformin reduce diabetes incidence in subjects with impaired glucose tolerance (IGT), their effects on lipoprotein subfractions have not been studied.
OBJECTIVE: The objective of the study was to characterize the effects of ILS and metformin vs placebo interventions on lipoprotein subfractions in the Diabetes Prevention Program.
DESIGN: This was a randomized clinical trial, testing the effects of ILS, metformin, and placebo on diabetes development in subjects with IGT. PARTICIPANTS: Selected individuals with IGT randomized in the Diabetes Prevention Program participated in the study.
INTERVENTIONS: Interventions included randomization to metformin 850 mg or placebo twice daily or ILS aimed at a 7% weight loss using a low-fat diet with increased physical activity. MAIN OUTCOME MEASURES: Lipoprotein subfraction size, density, and concentration measured by magnetic resonance and density gradient ultracentrifugation at baseline and 1 year were measured.
RESULTS: ILS decreased large and buoyant very low-density lipoprotein, small and dense low-density lipoprotein (LDL), and small high-density lipoprotein (HDL) and raised large HDL. Metformin modestly reduced small and dense LDL and raised small and large HDL. Change in insulin resistance largely accounted for the intervention-associated decreases in large very low-density lipoprotein, whereas changes in body mass index (BMI) and adiponectin were strongly associated with changes in LDL. Baseline and a change in adiponectin were related to change in large HDL, and BMI change associated with small HDL change. The effect of metformin to increase small HDL was independent of adiponectin, BMI, and insulin resistance.
CONCLUSION: ILS and metformin treatment have favorable effects on lipoprotein subfractions that are primarily mediated by intervention-related changes in insulin resistance, BMI, and adiponectin. Interventions that slow the development of diabetes may also retard the progression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979954      PMCID: PMC3790618          DOI: 10.1210/jc.2013-1452

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

Review 1.  Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.

Authors:  Elias J Jeyarajah; William C Cromwell; James D Otvos
Journal:  Clin Lab Med       Date:  2006-12       Impact factor: 1.935

Review 2.  The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype.

Authors:  John D Brunzell; Alberto Zambon; Samir S Deeb
Journal:  Biochim Biophys Acta       Date:  2011-09-25

3.  Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.

Authors:  Robert Ratner; Ronald Goldberg; Steven Haffner; Santica Marcovina; Trevor Orchard; Sarah Fowler; Marinella Temprosa
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

4.  Lipoprotein response to a National Cholesterol Education Program step II diet with and without energy restriction.

Authors:  M M Flynn; J M Zmuda; D Milosavljevic; M J Caldwell; P N Herbert
Journal:  Metabolism       Date:  1999-07       Impact factor: 8.694

5.  Effects of the amount and intensity of exercise on plasma lipoproteins.

Authors:  William E Kraus; Joseph A Houmard; Brian D Duscha; Kenneth J Knetzger; Michelle B Wharton; Jennifer S McCartney; Connie W Bales; Sarah Henes; Gregory P Samsa; James D Otvos; Krishnaji R Kulkarni; Cris A Slentz
Journal:  N Engl J Med       Date:  2002-11-07       Impact factor: 91.245

6.  Postheparin plasma lipoprotein and hepatic lipase are determinants of hypo- and hyperalphalipoproteinemia.

Authors:  T Kuusi; C Ehnholm; J Viikari; R Härkönen; E Vartiainen; P Puska; M R Taskinen
Journal:  J Lipid Res       Date:  1989-08       Impact factor: 5.922

Review 7.  Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.

Authors:  Martin Adiels; Sven-Olof Olofsson; Marja-Riitta Taskinen; Jan Borén
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07       Impact factor: 8.311

8.  Reversal of small, dense LDL subclass phenotype by normalization of adiposity.

Authors:  Patty W Siri-Tarino; Paul T Williams; Harriet S Fernstrom; Robin S Rawlings; Ronald M Krauss
Journal:  Obesity (Silver Spring)       Date:  2009-06-04       Impact factor: 5.002

9.  LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management.

Authors:  William C Cromwell; James D Otvos; Michelle J Keyes; Michael J Pencina; Lisa Sullivan; Ramachandran S Vasan; Peter W F Wilson; Ralph B D'Agostino
Journal:  J Clin Lipidol       Date:  2007-12       Impact factor: 4.766

Review 10.  Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.

Authors:  Molly C Carr; John D Brunzell
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

View more
  39 in total

Review 1.  Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.

Authors:  Vanita R Aroda; William C Knowler; Jill P Crandall; Leigh Perreault; Sharon L Edelstein; Susan L Jeffries; Mark E Molitch; Xavier Pi-Sunyer; Christine Darwin; Brandy M Heckman-Stoddard; Marinella Temprosa; Steven E Kahn; David M Nathan
Journal:  Diabetologia       Date:  2017-08-02       Impact factor: 10.122

Review 2.  Lifestyle interventions in preventing new type 2 diabetes in Asian populations.

Authors:  Pietro Amedeo Modesti; Giorgio Galanti; Piergiuseppe Cala'; Maria Calabrese
Journal:  Intern Emerg Med       Date:  2015-10-16       Impact factor: 3.397

3.  Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance.

Authors:  Irina Shalaurova; Margery A Connelly; W Timothy Garvey; James D Otvos
Journal:  Metab Syndr Relat Disord       Date:  2014-06-24       Impact factor: 1.894

4.  Effect of relative weight group change on nuclear magnetic resonance spectroscopy derived lipoprotein particle size and concentrations among adolescents.

Authors:  Russell Jago; Kimberly L Drews; James D Otvos; Gary D Foster; Marsha D Marcus; John B Buse; Michele Mietus-Snyder; Steven M Willi
Journal:  J Pediatr       Date:  2014-02-05       Impact factor: 4.406

Review 5.  Metformin as a Tool to Target Aging.

Authors:  Nir Barzilai; Jill P Crandall; Stephen B Kritchevsky; Mark A Espeland
Journal:  Cell Metab       Date:  2016-06-14       Impact factor: 27.287

Review 6.  The role of advanced lipid testing in the prediction of cardiovascular disease.

Authors:  Alvin Chandra; Anand Rohatgi
Journal:  Curr Atheroscler Rep       Date:  2014-03       Impact factor: 5.113

7.  Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.

Authors:  Ronald B Goldberg; Marinella Temprosa; Lisa Mele; Trevor Orchard; Kieren Mather; George Bray; Edward Horton; Abbas Kitabchi; Jonathan Krakoff; Santica Marcovina; Leigh Perreault; Neil White
Journal:  Metabolism       Date:  2015-12-02       Impact factor: 8.694

8.  Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium.

Authors:  Ronald B Goldberg; Vanita R Aroda; David A Bluemke; Elizabeth Barrett-Connor; Matthew Budoff; Jill P Crandall; Dana Dabelea; Edward S Horton; Kieren J Mather; Trevor J Orchard; David Schade; Karol Watson; Marinella Temprosa
Journal:  Circulation       Date:  2017-05-05       Impact factor: 29.690

9.  Prevention of Diabetes Through the Lifestyle Intervention: Lessons Learned from the Diabetes Prevention Program and Outcomes Study and its Translation to Practice.

Authors:  Mary A Hoskin; George A Bray; Kathy Hattaway; Prajakta A Khare-Ranade; Jeremy Pomeroy; Linda N Semler; Valarie A Weinzierl; Judith Wylie-Rosett
Journal:  Curr Nutr Rep       Date:  2014-12-01

10.  Targeting low-density lipoprotein and dysmetabolism in type 2 diabetes mellitus.

Authors:  Ronald Goldberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-03       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.